COMPLETED

A Clinical Study of How Coffee and Tea Affect Enlicitide in Healthy Volunteers (MK-0616-040)

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this study is to learn what happens to enlicitide in a person's body over time when enlicitide is taken at the same time as coffee or tea. Researchers will measure the amount of enlicitide in the blood when taken with coffee or tea compared with enlicitide taken with water.

Official Title

A Clinical Study to Evaluate the Effects of Coffee and Tea on the Pharmacokinetics of Enlicitide in Healthy Adult Participants

Quick Facts

Study Start:2025-07-03
Study Completion:2025-08-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT07044479

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Is in good health
  2. * Is a non-smoker for at least 3 months prior to study entry
  3. * Part 1 only: Consumes at least 1 cup of caffeinated coffee per day
  4. * Part 2 only: Consumes at least 1 cup of caffeinated tea per day
  1. * Has a history or presence of clinically significant medical or psychiatric condition or disease
  2. * History of gastrointestinal disease which might affect food and drug absorption, or has had gastric bypass or similar surgery.

Contacts and Locations

Principal Investigator

Medical Director
STUDY_DIRECTOR
Merck Sharp & Dohme LLC

Study Locations (Sites)

Celerion, Inc. ( Site 0001)
Tempe, Arizona, 85283
United States

Collaborators and Investigators

Sponsor: Merck Sharp & Dohme LLC

  • Medical Director, STUDY_DIRECTOR, Merck Sharp & Dohme LLC

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-03
Study Completion Date2025-08-28

Study Record Updates

Study Start Date2025-07-03
Study Completion Date2025-08-28

Terms related to this study

Additional Relevant MeSH Terms

  • Healthy